Gladstone Institutional Advisory LLC Purchases 8,810 Shares of TransMedics Group, Inc. $TMDX

Gladstone Institutional Advisory LLC boosted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 111.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,694 shares of the company’s stock after acquiring an additional 8,810 shares during the quarter. Gladstone Institutional Advisory LLC’s holdings in TransMedics Group were worth $1,873,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Opal Wealth Advisors LLC bought a new stake in shares of TransMedics Group during the 2nd quarter valued at about $26,000. Salomon & Ludwin LLC purchased a new position in shares of TransMedics Group in the third quarter worth approximately $28,000. Sound Income Strategies LLC bought a new stake in TransMedics Group during the second quarter valued at approximately $48,000. Elevation Point Wealth Partners LLC purchased a new stake in TransMedics Group during the second quarter valued at approximately $48,000. Finally, EverSource Wealth Advisors LLC raised its position in TransMedics Group by 72.0% in the second quarter. EverSource Wealth Advisors LLC now owns 485 shares of the company’s stock worth $65,000 after acquiring an additional 203 shares during the period. Institutional investors own 99.67% of the company’s stock.

Insider Transactions at TransMedics Group

In other news, Director David Weill sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the sale, the director directly owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This represents a 29.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 13,062 shares of company stock worth $1,797,634. 7.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TMDX. Evercore ISI began coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price objective for the company. Needham & Company LLC boosted their price target on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday, December 8th. Jefferies Financial Group started coverage on TransMedics Group in a research report on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Sunday, December 28th. Finally, Zacks Research downgraded TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Stock Up 3.5%

TMDX opened at $137.27 on Thursday. The firm has a 50-day simple moving average of $128.91 and a two-hundred day simple moving average of $122.12. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $156.00. The company has a market capitalization of $4.69 billion, a PE ratio of 55.57 and a beta of 2.03. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.29. The firm had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The business’s revenue was up 32.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.12 earnings per share. Analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.